Organogenesis

About:

Organogenesis Inc. is a regenerative medicine company.

Website: http://www.organogenesis.com/

Top Investors: MidCap Financial, Eastward Capital Partners, Silicon Valley Bank

Description:

Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.

Total Funding Amount:

$485M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Canton, Massachusetts, United States

Founded Date:

1985-01-01

Contact Email:

alowe(AT)organo.com

Founders:

Eugene Bell

Number of Employees:

501-1000

Last Funding Date:

2021-08-09

IPO Status:

Public

© 2025 bioDAO.ai